Johnson & Johnson Set To Complete Acquisition Of Intra-Cellular Therapies By April 2, 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 01 2025
0mins
Should l Buy JNJ?
Source: NASDAQ.COM
Acquisition Details: Johnson & Johnson plans to complete its acquisition of Intra-Cellular Therapies on or around April 2, 2025, following shareholder approval. This transaction is expected to boost JNJ's sales growth by approximately 0.8% in 2025.
Financial Impact: The acquisition is projected to improve adjusted earnings per share by about $0.25 in 2025, with a reduction in earnings dilution to approximately $0.21 per share in 2026 as financing costs are offset by operational gains.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 243.470
Low
190.00
Averages
218.50
High
240.00
Current: 243.470
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Johnson & Johnson: A Resilient Healthcare Stock
- Defensive Healthcare Sector: Johnson & Johnson's stable performance during economic fluctuations is attributed to its extensive drug portfolio covering oncology and immunology, ensuring that patients will continue to require life-saving medications even in market downturns, thus maintaining stable financial results.
- Consistent Dividend Growth: As a 'Dividend King', Johnson & Johnson has increased its dividend for 63 consecutive years, demonstrating its ability to maintain payouts even during economic downturns, providing investors with a safety net during market crashes.
- Diversified Product Portfolio: The company's deep and diversified portfolio, along with its entrenched position in the healthcare sector, has led to steady revenue and earnings growth over decades, and this trend is unlikely to change even in future market crashes.
- Long-Term Stability: While Johnson & Johnson may not be a high-growth stock, its leadership in healthcare and strong underlying business make it a stable long-term investment choice, appealing to investors seeking reliable returns.
See More
Johnson & Johnson Announces Preliminary Results, Advancing Prostate Cancer Treatment
- Clinical Trial Progress: Johnson & Johnson's Phase 1b study of pasritamig (JNJ-78278343) combined with docetaxel shows that 64.7% of patients achieved over 50% PSA reduction, indicating significant clinical potential in treating metastatic castration-resistant prostate cancer, which could transform existing treatment paradigms.
- Safety Profile Analysis: The safety of this combination therapy aligns with that of docetaxel alone, with only 2% of patients experiencing grade 3 or higher adverse events related to pasritamig, demonstrating good tolerability and supporting further clinical development.
- Sustained Treatment Efficacy: Among treated patients, 39.2% achieved over 90% PSA reduction, reflecting not only the effectiveness of the treatment but also providing sustained disease control, thereby enhancing confidence in clinical application.
- Future Research Directions: Johnson & Johnson plans to further evaluate the efficacy of pasritamig in two ongoing Phase 3 studies, with the combination therapy offering new hope for prostate cancer patients, aligning with the company's strategic focus in oncology immunotherapy.
See More
Johnson & Johnson: A Resilient Healthcare Giant
- Diversified Healthcare Giant: Johnson & Johnson's strong foundation in the healthcare sector allows it to maintain stable financial performance even during economic fluctuations, particularly in market crashes where demand for life-saving medications remains constant, ensuring continued revenue growth.
- Broad Drug Coverage: J&J's pharmaceuticals span oncology, immunology, infectious diseases, and neuroscience, with patients only covering part of the costs while insurers cover the rest, enhancing the company's resilience against market downturns.
- Stable Dividend Policy: As a 'Dividend King', Johnson & Johnson has increased its dividend for 63 consecutive years, providing additional income security for investors during market crashes, which helps smooth out losses and enhances the appeal of holding its stock.
- Long-Term Growth Potential: While J&J may not lead in high-growth areas like artificial intelligence, its leadership in healthcare and robust underlying business make it a stable investment choice, ideal for investors seeking long-term compounded returns.
See More
Kenvue's Bid to Dismiss Lawsuit Rejected
- Lawsuit Progress: A Texas judge rejected Kenvue's attempt to dismiss a lawsuit filed by Attorney General Ken Paxton, which accuses the company of concealing the risks of autism and ADHD in children whose mothers took Tylenol, highlighting the legal scrutiny surrounding the company's potential liabilities.
- Details of Allegations: Paxton's case claims that Kenvue and Johnson & Johnson violated the Texas Uniform Fraudulent Transfer Act by fraudulently transferring liabilities to Kenvue to shield their assets from lawsuits, which could expose the company to greater legal risks.
- Company's Response Measures: Kenvue has yet to respond to media requests for comments but has set up a dedicated website to address the claims, indicating the company's proactive approach to crisis management.
- Historical Context: Tylenol was previously sold by Johnson & Johnson Consumer Health before Kenvue's spin-off via IPO in 2023, and the ongoing lawsuit could impact its market image and future business development.
See More
Barron’s Top Fund Families for 2025
Opportunity for Fund Managers: Last year provided a significant opportunity for skilled fund managers to demonstrate their capabilities in navigating market challenges.
Market Conditions: The financial landscape presented unique conditions that allowed for strategic investment decisions and potential gains.
Performance Evaluation: The year served as a benchmark for assessing the effectiveness and decision-making skills of fund managers.
Investor Expectations: Investors were keenly observing how fund managers adapted to the evolving market, influencing future investment strategies.
See More
ACR Alpine Capital Increases Stake in Arrow Electronics
- Share Acquisition: ACR Alpine Capital Research acquired an additional 1,028,778 shares of Arrow Electronics in Q4 2026, increasing the position's value by $87 million, reflecting confidence in the company's future growth potential.
- Market Performance: As of February 4, 2026, Arrow Electronics shares traded at $137.99, up 21.3% over the past year, outperforming the S&P 500 by 7.27 percentage points, indicating strong market performance.
- Revenue Growth: Arrow Electronics reported a 10% increase in annual revenue, exceeding $30 billion, highlighting a recovery across various sectors including automotive and electronics, which enhances its competitive position.
- Industry Outlook: With the ISM Manufacturing PMI rising above 50, signaling a broader recovery in manufacturing, Arrow Electronics' strategy to shift investments towards high-margin areas positions it well to capitalize on future growth opportunities.
See More
Johnson & Johnson: A Resilient Healthcare Stock
- Defensive Healthcare Sector: Johnson & Johnson's stable performance during economic fluctuations is attributed to its extensive drug portfolio covering oncology and immunology, ensuring that patients will continue to require life-saving medications even in market downturns, thus maintaining stable financial results.
- Consistent Dividend Growth: As a 'Dividend King', Johnson & Johnson has increased its dividend for 63 consecutive years, demonstrating its ability to maintain payouts even during economic downturns, providing investors with a safety net during market crashes.
- Diversified Product Portfolio: The company's deep and diversified portfolio, along with its entrenched position in the healthcare sector, has led to steady revenue and earnings growth over decades, and this trend is unlikely to change even in future market crashes.
- Long-Term Stability: While Johnson & Johnson may not be a high-growth stock, its leadership in healthcare and strong underlying business make it a stable long-term investment choice, appealing to investors seeking reliable returns.
See More
Johnson & Johnson Announces Preliminary Results, Advancing Prostate Cancer Treatment
- Clinical Trial Progress: Johnson & Johnson's Phase 1b study of pasritamig (JNJ-78278343) combined with docetaxel shows that 64.7% of patients achieved over 50% PSA reduction, indicating significant clinical potential in treating metastatic castration-resistant prostate cancer, which could transform existing treatment paradigms.
- Safety Profile Analysis: The safety of this combination therapy aligns with that of docetaxel alone, with only 2% of patients experiencing grade 3 or higher adverse events related to pasritamig, demonstrating good tolerability and supporting further clinical development.
- Sustained Treatment Efficacy: Among treated patients, 39.2% achieved over 90% PSA reduction, reflecting not only the effectiveness of the treatment but also providing sustained disease control, thereby enhancing confidence in clinical application.
- Future Research Directions: Johnson & Johnson plans to further evaluate the efficacy of pasritamig in two ongoing Phase 3 studies, with the combination therapy offering new hope for prostate cancer patients, aligning with the company's strategic focus in oncology immunotherapy.
See More
Johnson & Johnson: A Resilient Healthcare Giant
- Diversified Healthcare Giant: Johnson & Johnson's strong foundation in the healthcare sector allows it to maintain stable financial performance even during economic fluctuations, particularly in market crashes where demand for life-saving medications remains constant, ensuring continued revenue growth.
- Broad Drug Coverage: J&J's pharmaceuticals span oncology, immunology, infectious diseases, and neuroscience, with patients only covering part of the costs while insurers cover the rest, enhancing the company's resilience against market downturns.
- Stable Dividend Policy: As a 'Dividend King', Johnson & Johnson has increased its dividend for 63 consecutive years, providing additional income security for investors during market crashes, which helps smooth out losses and enhances the appeal of holding its stock.
- Long-Term Growth Potential: While J&J may not lead in high-growth areas like artificial intelligence, its leadership in healthcare and robust underlying business make it a stable investment choice, ideal for investors seeking long-term compounded returns.
See More
Kenvue's Bid to Dismiss Lawsuit Rejected
- Lawsuit Progress: A Texas judge rejected Kenvue's attempt to dismiss a lawsuit filed by Attorney General Ken Paxton, which accuses the company of concealing the risks of autism and ADHD in children whose mothers took Tylenol, highlighting the legal scrutiny surrounding the company's potential liabilities.
- Details of Allegations: Paxton's case claims that Kenvue and Johnson & Johnson violated the Texas Uniform Fraudulent Transfer Act by fraudulently transferring liabilities to Kenvue to shield their assets from lawsuits, which could expose the company to greater legal risks.
- Company's Response Measures: Kenvue has yet to respond to media requests for comments but has set up a dedicated website to address the claims, indicating the company's proactive approach to crisis management.
- Historical Context: Tylenol was previously sold by Johnson & Johnson Consumer Health before Kenvue's spin-off via IPO in 2023, and the ongoing lawsuit could impact its market image and future business development.
See More
Barron’s Top Fund Families for 2025
Opportunity for Fund Managers: Last year provided a significant opportunity for skilled fund managers to demonstrate their capabilities in navigating market challenges.
Market Conditions: The financial landscape presented unique conditions that allowed for strategic investment decisions and potential gains.
Performance Evaluation: The year served as a benchmark for assessing the effectiveness and decision-making skills of fund managers.
Investor Expectations: Investors were keenly observing how fund managers adapted to the evolving market, influencing future investment strategies.
See More
ACR Alpine Capital Increases Stake in Arrow Electronics
- Share Acquisition: ACR Alpine Capital Research acquired an additional 1,028,778 shares of Arrow Electronics in Q4 2026, increasing the position's value by $87 million, reflecting confidence in the company's future growth potential.
- Market Performance: As of February 4, 2026, Arrow Electronics shares traded at $137.99, up 21.3% over the past year, outperforming the S&P 500 by 7.27 percentage points, indicating strong market performance.
- Revenue Growth: Arrow Electronics reported a 10% increase in annual revenue, exceeding $30 billion, highlighting a recovery across various sectors including automotive and electronics, which enhances its competitive position.
- Industry Outlook: With the ISM Manufacturing PMI rising above 50, signaling a broader recovery in manufacturing, Arrow Electronics' strategy to shift investments towards high-margin areas positions it well to capitalize on future growth opportunities.
See More
